Skip to content

Prospective randomized controlled trial of anticoagulant therapy in the treatment of recurrent spontaneous abortion with thrombophilia

Prospective randomized controlled trial of anticoagulant therapy in the treatment of recurrent spontaneous abortion with thrombophilia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009417
Enrollment
Unknown
Registered
2016-10-15
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

recurrent spontaneous abortion with thrombophilla

Interventions

LMWH plus LDA Group:LMWH plus LDA
LDA Group:LDA
LMWH group:Low molecular weight heparin

Sponsors

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Woman who had their Second miscarriage before 12(th) week of gestation.The patient who is diagnosed as thrombophilia with recurrent pregnancy loss. Signed consent form.

Exclusion criteria

Exclusion criteria: 1. having experiencedsevere allergies, trauma history and/or operation history within 3 months; 2. with a history of mental illness and/or family history of mental illness; 3. limb disabled; 4. taking medicine within one month; 5. suffering major events or having mood swings; 6. with a history of recurrent pregnancy loss; 7. having internal and surgical disease(after having variety of physical examination such as electrocardiogram/hepatic and renal function/blood routine and urine rotine); 8.chromosome aberrations in anyone of the couple. 9.having contraindications to asprin and low molecular weight heparin.

Design outcomes

Primary

MeasureTime frame
fetus chromosome;antithrombin, AT;protein C;protein S;D-Dimer;Factor V Leiden Mutation;MTHFR C677T Mutation;PAI-1 4G/5G Mutation;Factor XIII V34L Mutation;Anti-cardiolipin antibodies;Anti-ß2 Glycoprotein I Antibodies;

Countries

China

Contacts

Public ContactBao Shihua

Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine

baoshihua@tongji.edu.cn+86 13916772579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026